0001628280-26-016814
SEC filingFoghorn Therapeutics Inc. reported a net loss of $74.3 million for fiscal year 2025, driven by significant operating expenses of $117.3 million that exceeded collaboration revenue of $30.9 million. The company generated a loss from operations of $86.4 million, partially offset by total other income of $12.1 million primarily from interest income. Cash flow from operations was negative $86.1 million, while investing activities provided $112.0 million mainly from maturities of marketable securities. The balance sheet shows total assets of $198.1 million with cash and equivalents of $80.9 million, but stockholders' deficit of $108.5 million due to accumulated deficit of $632.5 million. The company's financial position reflects ongoing research and development investments of $85.5 million as it advances its therapeutic pipeline.
Foghorn Therapeutics Inc. reported financial results for fiscal year 2025 ending December 31, 2025. The company generated collaboration revenue of $30.9 million while incurring total operating expenses of $117.3 million, resulting in a loss from operations of $86.4 million. Net loss for the period was $74.3 million, which included total other income of $12.1 million primarily from interest income of $8.7 million. Research and development expenses were $85.5 million, representing the largest component of operating expenses, while general and administrative expenses were $27.6 million. The company reported a comprehensive loss of $74.4 million, which included other comprehensive loss of $111,000 from unrealized losses on marketable securities. Net loss per share was $1.00 for both basic and diluted calculations based on weighted average common shares outstanding of 63.0 million.
The company's revenue for fiscal year 2025 consisted entirely of collaboration revenue totaling $30.9 million. No segment breakdown or geographic revenue mix was disclosed in the provided financial data. The revenue represents income from collaborative arrangements, which is the company's primary revenue source. No product sales or service revenue was reported. The financial statements do not provide comparative revenue figures from prior periods, preventing year-over-year growth analysis. The collaboration revenue appears to be recognized from contracts with customers, though specific details about collaboration partners or agreement terms are not included in the numerical data provided.
Foghorn Therapeutics reported negative operating margins due to operating expenses significantly exceeding revenue. With collaboration revenue of $30.9 million and total operating expenses of $117.3 million, the company's operating loss margin was substantial. Research and development expenses of $85.5 million represented approximately 73% of total operating expenses, reflecting the company's focus on advancing its therapeutic pipeline. General and administrative expenses of $27.6 million accounted for the remaining operating costs. The company recorded impairment of long-lived assets of $5.9 million and a gain on lease modification of $1.6 million during the period. No gross profit or gross margin figures were disclosed, as the company does not appear to have product cost of goods sold.
The company used $86.1 million in cash from operating activities during fiscal year 2025, primarily driven by the net loss of $74.3 million adjusted for non-cash items including stock-based compensation of $10.4 million and depreciation of $3.3 million. Investing activities provided $112.0 million in cash, mainly from proceeds from maturities of marketable securities of $243.3 million offset by purchases of marketable securities of $131.2 million. Financing activities provided $1.0 million from equity offerings and stock option exercises. The balance sheet shows total assets of $198.1 million including cash and equivalents of $80.9 million and marketable securities of $78.0 million. Total liabilities were $306.6 million with deferred revenue of $249.2 million, resulting in stockholders' deficit of $108.5 million. The company had accumulated deficit of $632.5 million.
The provided financial data does not include management guidance, strategic priorities, or specific risk factors from the filing's narrative sections. The numerical data shows the company continues to invest heavily in research and development with $85.5 million in R&D expenses during the period. The balance sheet indicates liquidity with $80.9 million in cash and equivalents and $78.0 million in marketable securities, though the stockholders' deficit position of $108.5 million reflects cumulative losses. The company's cash flow from operations remains negative at $86.1 million, indicating ongoing funding requirements for operations. No forward-looking statements or projections are included in the numerical financial data provided.